Diabète De Type 2
Articles
Pooled analysis: Interventional and observational studies
A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.1
Act early, think holistically for your patients with Type 2 diabetes at very high cardiovascular risk
People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.1 The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.2,3
Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?
Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.
How Does Glycaemic Control Impact Complications in Type 2 Diabetes?
Summary of The UK Prospective Diabetes Study (UKPDS).
Leave site modal
Vous êtes sur le point de quitter campus.sanofi/be. Sanofi n'est pas responsable du contenu de ce site externe.
Les contenus accessibles par ce site sont destinés exclusivement aux Professionnels de Santé.
Les contenus accessibles par ce site sont destinés
exclusivement aux Professionnels de Santé.
Sanofi met a votre disposition, sur un portail unique dédié aux professionnels de santé, des contenus exclusifs comprenant des contenus scientifiques et des outils pour votre pratique quotidienne.
